EXHIBIT 99.2


PRESS RELEASE                                             Source: CryoLife, Inc.

                  Albert E. Heacox, Ph.D. Assumes Senior Vice
                     President of Research and Development
                          Position for CryoLife, Inc.
                        Tuesday December 14, 8:30 am ET

ATLANTA, Dec. 14  /PRNewswire-FirstCall/  -- CryoLife, Inc. (NYSE: CRY - News) a
biomaterials  and  biosurgical  device  company,  announced today that Albert E.
Heacox,  Ph.D. has assumed the position of Senior Vice President of Research and
Development  of  CryoLife,  Inc.  Reporting  to Dr.  Heacox  will be  CryoLife's
Research  and  Development  Laboratory,  Product  and  Process  Engineering  and
Aurazyme Pharmaceuticals' Research Department.  Dr. Heacox, (54) joined CryoLife
in 1985 as Director of  Laboratory  Operations.  In 1989 he was promoted to Vice
President of  Laboratory  Operations  and then in 2000 he was promoted to Senior
Vice President of Laboratory  Operations for the Company. In his new position he
will continue to report to Steven G. Anderson, President and CEO of CryoLife.

Albert E.  Heacox  completed  his B.S.  and M.S.  degrees  in biology at Adelphi
University  in New York in 1971 and 1974  respectively.  In 1980 he received his
Ph.D.  in zoology from  Washington  State  University.  In 1981 he completed his
post-doctorate  training  in cell  biology  from The  University  of  Cologne in
Germany.  Prior to joining CryoLife in 1985, he was a research scientist for the
U.S.  Department of  Agriculture  in Fargo,  North Dakota.  He replaces Kirby S.
Black, Ph.D. who resigned to pursue other interests.

"CryoLife has an extensive  portfolio of new products in the Company's  research
pipeline and Al Heacox is the perfect person to bring these new technologies and
products to fruition," said Steven G. Anderson, President and CEO. "In addition,
Dr. Heacox has over twenty years  experience in preserving  mammalian  cells and
tissues  and will  shepherd  the  Company's  many new  tissue  preservation  and
materials  technologies  going forward."  Anderson added, "We wish Dr. Black the
best in his new endeavors and thank him for his many contributions to CryoLife."

About CryoLife, Inc.

Founded in 1984,  CryoLife,  Inc. is a leader in the processing and distribution
of  implantable  living  human  tissues for use in  cardiovascular  and vascular
surgeries  throughout  the  United  States and  Canada.  The  Company's  BioGlue
Surgical  Adhesive is FDA  approved as an adjunct to sutures and staples for use
in adult  patients in open surgical  repair of large vessels and is CE marked in
the European  Community and approved in Canada for use in soft tissue repair and
approved in Australia for use in vascular and pulmonary sealing and repair.  The
Company also  manufactures the SG Model #100 vascular graft,  which is CE marked
for distribution within the European Community.


For  additional  information  about  the  company,  visit  CryoLife's  web site:
http://www.cryolife.com

Contact: Joseph T. Schepers
Vice President, Corporate Communications (770) 419-3355

Source: CryoLife, Inc.